急性心肌梗死完全血运重建与仅罪犯病变血运重建:随机试验个体患者数据Meta分析
该个体患者数据Meta分析纳入6项随机对照试验共8836例急性ST段抬高型或非ST段抬高型心肌梗死合并多支病变患者,比较完全血运重建策略(对非罪犯病变行PCI)与仅罪犯病变PCI策略。中位随访36.0个月,完全血运重建组心血管死亡或新发心肌梗死发生率为9.0%,仅罪犯病变组为11.5%(HR 0.76,95%CI 0.67-0.87,p<0.0001);心血管死亡分别为3.6%与4.6%(HR 0.76,95%CI 0.62-0.93,p=0.0091);全因死亡分别为7.2%与8.1%(HR 0.85,95%CI 0.73-0.99,p=0.039)。非心血管死亡两组相似。作者认为这些数据提供了迄今最强有力的证据,表明完全血运重建改善重要心血管临床结局。
要点
- 急性心肌梗死合并多支病变患者,完全血运重建组心血管死亡或新发心肌梗死9.0% vs 仅罪犯病变组11.5%,HR 0.76(95%CI 0.67-0.87),p<0.0001。
- 完全血运重建组心血管死亡3.6% vs 仅罪犯病变组4.6%,HR 0.76(95%CI 0.62-0.93),p=0.0091。
- 完全血运重建组全因死亡7.2% vs 仅罪犯病变组8.1%,HR 0.85(95%CI 0.73-0.99),p=0.039。
- 完全血运重建组新发心肌梗死6.0% vs 仅罪犯病变组7.8%,HR 0.76(95%CI 0.65-0.90),p=0.0011。
- 非心血管死亡两组相似:完全血运重建组3.6% vs 仅罪犯病变组3.5%,HR 0.98(95%CI 0.78-1.22),p=0.85。
适用人群与场景
- 纳入标准:随机对照试验入组至少250例患者,比较完全血运重建策略(PCI)与仅罪犯病变PCI策略,入组急性ST段抬高型心肌梗死或非ST段抬高型心肌梗死患者。
- 共纳入6项随机对照试验8836例患者,中位年龄65.8岁(IQR 57.0-76.0),女性2088例(23.6%),男性6748例(76.4%)。
- ST段抬高型心肌梗死7768例(87.9%),非ST段抬高型心肌梗死1068例(12.1%)。
研究设计与关键结果
- 研究类型:个体患者数据Meta分析,纳入6项随机对照试验,共8836例急性心肌梗死合并多支病变患者,比较完全血运重建策略与仅罪犯病变PCI策略。
- 主要终点心血管死亡或新发心肌梗死:完全血运重建组382/4259例(9.0%)vs 仅罪犯病变组528/4577例(11.5%),HR 0.76(95%CI 0.67-0.87),p<0.0001;中位随访36.0个月(IQR 30.6-48.0)。
- 心血管死亡:完全血运重建组155/4259例(3.6%)vs 仅罪犯病变组209/4577例(4.6%),HR 0.76(95%CI 0.62-0.93),p=0.0091。
- 全因死亡(次要终点):完全血运重建组308/4259例(7.2%)vs 仅罪犯病变组370/4577例(8.1%),HR 0.85(95%CI 0.73-0.99),p=0.039。
- 非心血管死亡:完全血运重建组153/4259例(3.6%)vs 仅罪犯病变组161/4577例(3.5%),HR 0.98(95%CI 0.78-1.22),p=0.85。
- 新发心肌梗死:完全血运重建组255/4259例(6.0%)vs 仅罪犯病变组357/4577例(7.8%),HR 0.76(95%CI 0.65-0.90),p=0.0011。
证据类型、等级与局限
- 证据类型:个体患者数据Meta分析,纳入6项随机对照试验。
- 预设α水平0.04,心血管死亡单独分析在心血管死亡或新发心肌梗死复合终点达到预设α水平后方进行分层检验。
- 作者结论:这些数据提供了迄今最强有力且最稳健的证据,表明完全血运重建改善重要心血管临床结局。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在急性心肌梗死合并多支病变患者中,与仅罪犯病变PCI策略相比,完全血运重建降低心血管死亡或新发心肌梗死复合终点以及心血管死亡,全因死亡亦较低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients presenting with acute coronary syndromes and multivessel coronary artery disease, the question of whether to undertake a strategy of complete revascularisation in cases in which percutaneous coronary intervention (PCI) is performed routinely on non-culprit lesions (in addition to the culprit lesion) or whether to restrict PCI only to the culprit lesion is a common dilemma. The Complete Revascularisation Trialists' Collaboration aimed to determine, based on the totality of data from randomised trials, the effect of a complete revascularisation strategy on major cardiovascular events and whether it reduces cardiovascular death.
METHODS: In this individual patient data meta-analysis, trials were included if they enrolled at least 250 patients, compared a complete revascularisation strategy (with PCI) to a culprit lesion-only PCI strategy, and enrolled patients presenting with acute ST-segment elevation myocardial infarction or non-ST-segment elevation myocardial infarction. To ensure that no trials were overlooked, we searched Ovid MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) for randomised controlled trials published between 1996 and Sept 15, 2025. The primary outcomes were the composite of cardiovascular death or new myocardial infarction and cardiovascular death alone. Hierarchical testing of cardiovascular death alone was planned contingent on reduction in cardiovascular death or new myocardial infarction based on the prespecified alpha level of 0·04. A one-stage individual patient data meta-analysis was performed using a Cox frailty model. All-cause death was the secondary outcome; non-cardiovascular death and new myocardial infarction were additional outcomes. All analyses included all randomly assigned patients. The meta-analysis was registered in PROSPERO, CRD420251124098.
FINDINGS: Six randomised controlled trials involving 8836 individuals were included. The median age was 65·8 years (IQR 57·0-76·0), and 2088 (23·6%) patients were female and 6748 (76·4%) were male. Overall, 7768 (87·9%) patients presented with ST-segment elevation myocardial infarction and 1068 (12·1%) with non-ST-segment elevation myocardial infarction. At a median follow-up of 36·0 months (IQR 30·6-48·0), cardiovascular death or new myocardial infarction occurred in 382 (9·0%) of 4259 patients in the complete revascularisation group compared with 528 (11·5%) of 4577 patients in the culprit lesion-only group (hazard ratio [HR] 0·76 [95% CI 0·67-0·87], p<0·0001). There were 155 (3·6%) cardiovascular deaths in the complete revascularisation group compared with 209 (4·6%) in the culprit lesion-only group (HR 0·76 [95% CI 0·62-0·93], p=0·0091). All-cause death occurred in 308 (7·2%) patients in the complete revascularisation group compared with 370 (8·1%) patients in the culprit lesion-only group (HR 0·85 [95% CI 0·73-0·99], p=0·039). Non-cardiovascular death was similar between the groups (153 [3·6%] in the complete revascularisation group vs 161 [3·5%] in the culprit lesion-only group; HR 0·98 [95% CI 0·78-1·22], p=0·85). Complete revascularisation reduced new myocardial infarctions compared with culprit lesion-only PCI (255 [6·0%] vs 357 [7·8%]; HR 0·76 [95% CI 0·65-0·90], p=0·0011).
INTERPRETATION: In patients presenting with acute myocardial infarction and multivessel disease, complete revascularisation reduced the composite of cardiovascular death or new myocardial infarction as well as cardiovascular death alone compared with a culprit lesion-only PCI strategy. In addition, all-cause death was lower with complete revascularisation. These data provide the strongest and most robust evidence to date that complete revascularisation improves important cardiovascular clinical outcomes.
参考来源
- Mehta SR, Tiong DTW, Böhm F, et al. Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials. Lancet. 2025. PMID: 41223860. doi:10.1016/S0140-6736(25)02170-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。